ClinicalTrials.gg
CompletedNCT06952127TEPCOUpdated Apr 30, 2025

Feasibility and Preliminary Efficacy of a Group-based Telerehabilitation Program in People With Post-COVID-19 Sequelae (TEPCO).

An interventional study of Rehabilitation program in Long COVID-19 Syndrome, Long COVID and Long COVID Syndrome, sponsored by Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Apr 2023, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.

Enrollment
29th of 33
22 · median 82
Started
2023
with 7 others
No phase
23 of 40
6 open now
Registered
35th of 40
by date
Lead sponsor
2 of 40
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec

Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is the 29th largest by enrollment of the 33 interventional ones that give a count, is one of 8 that started in 2023, is one of 23 with no phase, and was the 35th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study pilot randomized controlled study is to evaluate the feasibility of the study procedures and to compare the preliminary efficacy of a rehabilitation program given in a "remote" (telerehabilitation) or "face-to-face" model for adult patients who had confirmed SARS-CoV-2 infection and still have symptoms after eight weeks of infection. The main question it aims to answer is:

  • Are the study procedures feasible?
  • Will the two groups have similar results for the preliminary efficacy outcomes?

Researchers will compare group telerehabilitation to a face-to-face group to see if it's comparable.

Participants will:

  • Take part in a 60-minute training session, 3 times a week in person or remotely
  • Visit the clinic before starting the training program and after 8 weeks of training
  • Keep a diary of their symptoms, if any
03

Conditions studied

  • Long COVID-19 Syndrome
  • Long COVID
  • Long COVID Syndrome

Keywords

  • telerehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients (≥18 years)
  • confirmed SARS-CoV-2 infection defined by positive polymerase chain reaction (PCR) testing and/or antigen test results
  • referred to the pneumology clinic for a modified British Medical Research Council (mMRC) dyspnea score of 2-3 after a minimum of eight weeks of infection
  • VO₂max of less than 80% of the predicted value
  • receiving a medical prescription for rehabilitation following initial assessment by a pulmonologist
  • being able to walk independently
  • providing
  • having a good internet connection (i.e., a minimum download speed of 4 Mbps and an upload speed of 4 Mbps)
  • being in possession of a computer or tablet equipped with a camera enabling videoconferencing.

Exclusion criteria

Exclusion Criteria:

  • requiring in-hospital rehabilitation at discharge
  • evidence of medical instability (i.e., moderate or severe cardiac disease, ischemic or severe hemorrhagic stroke, or neurodegenerative disease, unstable fracture)
  • history of severe cognitive or mental impairment
  • already enrolled in another rehabilitation program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Telerehabilitation group

    Rehabilitation program including cardiovascular, muscular and balance training and, if necessary, respiratory physiotherapy using the Teams platform supervised by a certified kinesiologist. The rehabilitation will be conducted 3 times a week for 8 weeks in group of 5 or 6 persons.

    Other: Rehabilitation program

  • Active comparator
    Face-to-face group

    Rehabilitation program including cardiovascular, muscular and balance training and, if necessary, respiratory physiotherapy at the university kinesiology clinic supervised by a certified kinesiologist. The rehabilitation will be conducted 3 times a week for 8 weeks in group of 5 or 6 persons.

    Other: Rehabilitation program

Interventions

  • OtherRehabilitation program

    * 5-minute warm-up including easy global exercises * 5 resistance training exercises targeting upper and lower muscle groups * 30 secondes break between sets * Cooldown with breathing and stretching exercises

06

What researchers measure

Primary outcomes

  1. The feasibility of study procedures

    This will be evaluated by % of participants that accept to participate in the study (recruitment rate), % of participants who drop out or withdraw from a study (attrition rate), % completed session (adherence rate); number of adverse events and % of participants satisfaction.

    Time frame: 8 weeks

Secondary outcomes

  1. Exercise capacity

    Pedaling time on a cycle ergometer at constant load (i.e., 60% of maximum load).

    Time frame: 8 weeks

  2. Walking capacity

    6-minute walk test Total distance walked in meters

    Time frame: 8 weeks

  3. Lower-limb endurance

    1-minute sit-to-stand test The number of completed sit-to-stand repetitions is record.

    Time frame: 8 weeks

  4. Physical performance

    Short Physical Performance Battery test Is made up of a set of three tests: standing static balance in three positions (score 0-4); lower limb strength and power through getting up and sitting on a chair(score 0-4); and walking speed at normal pace (score 0-4). And an overall score on 12.

    Time frame: 8 weeks

  5. Change in Independence in activities of daily living

    The Barthel Index Ten items are scored with a number of points (the scoring is as follows: 0 = unable, 1 = needs assistance/help, 2 = independent), and then a final score is calculated by summing the points awarded to each functional skill. The higher the score, the more independent the patient is.

    Time frame: 8 weeks

  6. Change in Clinical Frailty

    Clinical Frailty Scale (CFS) Frailty score ranging from 1 (very fit) to 9 (terminally ill)

    Time frame: 8 weeks

  7. Change in Quality of life

    Saint George's Hospital Respiratory Questionnaire (SGHRQ). Scores ranging from 0 to 100 are calculated for each component, as well as a total score that summarizes the responses to all items. A zero score indicates no impairment of quality of life, and higher scores indicate more limitations.

    Time frame: 8 weeks

07

Study locations

1 site
  • Centre hospitalier affilié universitaire régional
    Trois-Rivières, Quebec G8Z 3R9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Mar 2024, 11 months.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 11 months is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
Apr 30, 2025
StartActual
Apr 7, 2023
Primary completionActual
Mar 29, 2024
CompletionActual
Mar 29, 2024
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06952127
Lead sponsor
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Responsible party
Marie-Claude Lehoux (Principal Investigator, Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec) — Principal investigator
First posted
Apr 30, 2025
Start date
Apr 7, 2023
Primary completion
Mar 29, 2024
Completion
Mar 29, 2024
Last update
Apr 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion